StockNews.AI
ITCI
StockNews.AI
175 days

INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI

1. Investigation launched into ITCI's proposed sale to JNJ. 2. $132 cash offer per share faces legal scrutiny, possibly delaying process.

2m saved
Insight
Article

FAQ

Why Neutral?

The fixed $132 cash offer sets a clear acquisition target, yet the legal investigation introduces uncertainty. Similar historical deal reviews have led to temporary market hesitancy before resolution.

How important is it?

The proposed sale is a significant corporate event for ITCI, with potential delays from legal scrutiny affecting near-term valuations. The involvement of a well-known acquirer like JNJ further contributes to its relevance.

Why Short Term?

The legal review will likely impact ITCI’s price in the near term, with effects fading once the investigation is resolved.

Related Companies

JNJ
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellular Therapies, Inc. (NasdaqGS: ITCI) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Intra-Cellular will receive $132.00 in cash for each share of Intra-Cellular that they own. KSF is seeking to determine whether this consideration and the process t.

Related News